Combining RT with immunotherapy promotes the cross-priming of tumor-specific CD8+ T cells, stimulating the immune effector function of T cells and neutralizing the immunosuppressive effects of the tumor microenvironment [27]. The gene discussed is CD8A; the disease is neoplasm.